Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 3Primary Myelofibrosis 2Leukemia, Neutrophilic, Chronic 1

Interventions

fludarabine phosphate 10Cyclophosphamide 8Busulfan 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Antilymphocyte Serum 7Tacrolimus 6Methotrexate 5Cyclosporine 5thymoglobulin 4Melphalan 4Rituximab 3Radiotherapy 3Etoposide 3Cord Blood Stem Cell Transplantation 3Sirolimus 2Ondansetron 2Granulocyte Colony-Stimulating Factor 2Dexamethasone 2Cytarabine 2Carmustine 2Calcium Dobesilate 2Aprepitant 2ruxolitinib 1fludarabine 1fedratinib 1etoposide phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Neutrophilic, Chronic × fedratinib × Clear all
NCT05177211 2026-04-17

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Neutrophilic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡